Trajectories of α-fetoprotein and unresectable hepatocellular carcinoma outcomes receiving atezolizumab plus bevacizumab: a secondary analysis of IMbrave150 study

被引:0
作者
Linbin Lu
Peichan Zheng
Yan Pan
Shanshan Huang
Erqian Shao
Yan Huang
Xuewen Wang
Yayin Chen
Gongbao Cuo
Hongyi Yang
Wangting Guo
Yanhong Shi
Zhixian Wu
Xiong Chen
机构
[1] Mengchao Hepatobiliary Hospital of Fujian Medical University,Department of Oncology
[2] Fujian Medical University,Fujian Center for Safety Evaluation of New Drug
[3] Fujian Provincial Hospital of Fujian Medical University,Department of Oncology
[4] the First Affiliated Hospital of Nanchang University,Department of Oncology
[5] The Third Affiliated Hospital of Sun Yat-sen University Yuedong Hospital,Department of Oncology
[6] Quanzhou First Hospital Affiliated to Fujian Medical University,Department of Oncology
[7] The 900th Hospital of Joint Logistic Support Force,Department of Oncology
[8] PLA,Department of Hepatobiliary Disease
[9] Fuzong Clinical College of Fujian Medical University,undefined
[10] Dongfang Hospital of Xiamen University Medical College,undefined
来源
British Journal of Cancer | 2023年 / 129卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:620 / 625
页数:5
相关论文
共 119 条
[1]  
Galle PR(2019)Biology and significance of alpha-fetoprotein in hepatocellular carcinoma Liver Int 39 2214-29
[2]  
Foerster F(2009)New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy J Clin Oncol 27 446-52
[3]  
Kudo M(2009)Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma Oncologist 14 717-25
[4]  
Chan SL(2010)Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma Cancer 116 4590-6
[5]  
Llovet JM(2018)Changes in serum α-fetoprotein level predicts treatment response and survival in hepatocellular carcinoma patients and literature review J Formos Med Assoc 117 153-63
[6]  
Qin S(2019)Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma Liver Int 39 2184-89
[7]  
Chan SL(2020)Serum alpha-fetoprotein levels and clinical outcomes in the phase III CELESTIAL study of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma Clin Cancer Res 26 4795-804
[8]  
Mo FK(2020)Predictors of response and survival in immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma Cancers (Basel) 12 182-97
[9]  
Johnson PJ(2021)Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab Br J Cancer 124 1388-8
[10]  
Hui EP(2023)Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment Cancer Med 12 2731-402